癲癇市場：KOL 洞察

Epilepsy - KOL Insight

出版日期: 年間契約型資訊服務 | 出版商:

FirstWord Group | 英文

價格

簡介目錄

本報告調查癲癇市場，並提供了主要意見領袖對癲癇治療趨勢的最新見解。深入研究目前治療的有效性、新藥的潛力以及不斷發展的管理策略。還提到了新治療的未滿足需求和基準，並全面概述了癲癇治療的未來。

本報告中的主要品牌

Belviq (lorcaserin)
Briviact (brivaracetam)
Comfyde (carisbamate)
Diacomit (stiripentol)
Epidiolex/Epidyolex (cannabidiol)
EPX-100 (clemizole)
EQU-001 (ivermectin capsule formulation)

Fintepla (fenfluramine)
Fycompa (perampanel)
STK-001 (zorevunersen)
TAK 935 (soticlestat); Xcopri/Ontozry (cenobamate)
XEN1101 (azetukalner)
Ztalmy (ganaxolone)

公司列表

UCB
Jazz Pharmaceuticals
SK Life Science
Takeda
Marinus Pharmaceuticals
Xenon Pharmaceuticals

Eisai
Stoke Therapeutics
Epygenix Therapeutics
Biocodex
Equilibre Biopharmaceuticals

簡介目錄

Discover the latest insights from key opinion leaders on epilepsy treatment trends. This report delves into the efficacy of current therapies, the potential of emerging drugs, and evolving management strategies. It addresses unmet needs and benchmarks for new treatments, offering a comprehensive view of the future landscape in epilepsy care.

Key questions answered:

How do current epilepsy treatments compare in terms of efficacy, side effects, and ease of use?
Which upcoming epilepsy therapies show the most potential for improving patient outcomes?
What benchmarks must new epilepsy drugs meet to remain competitive in the market?
How will new treatments impact the current landscape of epilepsy medications?
How is epilepsy management expected to evolve for different patient populations?
What are the key unmet needs in existing epilepsy treatments that still need to be addressed?

Key brands covered in this report:

Belviq (lorcaserin)
Briviact (brivaracetam)
Comfyde (carisbamate)
Diacomit (stiripentol)
Epidiolex/Epidyolex (cannabidiol)
EPX-100 (clemizole)
EQU-001 (ivermectin capsule formulation)

Fintepla (fenfluramine)
Fycompa (perampanel)
STK-001 (zorevunersen)
TAK 935 (soticlestat); Xcopri/Ontozry (cenobamate)
XEN1101 (azetukalner)
Ztalmy (ganaxolone)

List of Companies:

UCB
Jazz Pharmaceuticals
SK Life Science
Takeda
Marinus Pharmaceuticals
Xenon Pharmaceuticals

Eisai
Stoke Therapeutics
Epygenix Therapeutics
Biocodex
Equilibre Biopharmaceuticals

Table of Tables

Executive summary

Treatment algorithm

Research objectives

Marketed therapies

Sodium channel blockers
- Carbamazepine-related antiseizure medications
- Xcopri/Ontozry (cenobamate; SK Life Science)

Neuromodulators

Briviact (brivaracetam; UCB)
- Key insights summary

GABAergic mechanisms

Benzodiapines (rescue medications)
- Key insights summary
- Ztalmy (ganaxolone; Marinus Pharmaceuticals)
- Diacomit (stiripentol; Biocodex)

Other modes of action

Epidiolex/Epidyolex (cannabidiol; Jazz Pharmaceuticals)
- Key insights summary
- Fintepla (fenfluramine; UCB)
- Fycompa (perampanel; Eisai)

Pipeline therapies

Late-stage drugs
- Belviq (lorcaserin; Eisai)
- TAK 935 (soticlestat; Takeda)
- Comfyde (carisbamate; SK Life Science)
Early-stage drugs
- XEN1101 (azetukalner; Xenon Pharmaceuticals)
- EPX-100 (clemizole; Epygenix Therapeutics)
- EQU-001 (ivermectin capsule formulation; Equilibre Biopharmaceuticals)
- STK-001 (zorevunersen; Stoke Therapeutics)

Future treatment paradigm

Key insights summary
- Anti-epileptogenesis and disease-modifying treatments emerge as key unmet needs in epilepsy, alongside improved diagnostics and targeted therapies